2025
Epidemiological and Clinical Features of Enterotoxigenic Escherichia coli (ETEC) Diarrhea in an Urban Slum in Dhaka, Bangladesh
Chowdhury F, Islam T, Ahmmed F, Akter A, Mwebia M, Im J, Rickett N, Mbae C, Aziz A, Ongadi B, Khanam F, Khan A, Firoj G, Rahman S, Park E, Haile K, Mwangi M, Ngugi B, Behute M, Kering K, Agampodi S, Kanungo S, Zaman K, Kariuki S, Qadri F, Clemens J. Epidemiological and Clinical Features of Enterotoxigenic Escherichia coli (ETEC) Diarrhea in an Urban Slum in Dhaka, Bangladesh. Open Forum Infectious Diseases 2025, 12: ofaf375. PMID: 40689249, PMCID: PMC12272338, DOI: 10.1093/ofid/ofaf375.Peer-Reviewed Original ResearchEnterotoxigenic Escherichia coliGt;45 yearsClinical featuresDynamic cohortEnterotoxigenic Escherichia coli diarrheaClosed cohortCluster Randomized Controlled TrialUrban slumsPopulation-based dataPopulation-based cohortOral cholera vaccineETEC diarrheaDiarrheal surveillanceEscherichia coli</i>Older adultsDiarrheal illnessCohort analysisVaccine trialsCholera vaccineCohortHealth problemsAged 1DiarrheaAge groupsGt;45The participation of people deprived of liberty in tuberculosis vaccine trials: should they be protected from research, or through research?
Andrews J, Charalambous S, Churchyard G, Cobelens F, Fernández-Escobar C, Frick M, Hanekom W, Hatherill M, Hill P, Pandey S, Rangaka M, White R, Lemos E, da Silva A, Croda J, Garcia-Basteiro A. The participation of people deprived of liberty in tuberculosis vaccine trials: should they be protected from research, or through research? The Lancet Infectious Diseases 2025 PMID: 40587989, DOI: 10.1016/s1473-3099(25)00305-6.Peer-Reviewed Original ResearchTuberculosis vaccine trialVaccine trialsHigh riskEffective tuberculosis vaccineHigh risk of developing diseaseAdult pulmonary tuberculosisRate of tuberculosisRisk of developing diseaseMycobacterium tuberculosis transmissionPulmonary tuberculosisClinical developmentTuberculosis vaccinesMedical researchEthical violationsLiberty rightsTuberculosis transmissionEfficacy trialsTuberculosisTuberculosis controlScientific progressLibertyPlanned trialsTrialsParticipation of peopleVaccineGlobal estimates of rotavirus vaccine efficacy and effectiveness: a rapid review and meta-regression analysis
Prunas O, Asare E, Sajewski E, Li Y, Pithawala Z, Weinberger D, Warren J, Armah G, Cunliffe N, Iturriza-Gómara M, Lopman B, Pitzer V. Global estimates of rotavirus vaccine efficacy and effectiveness: a rapid review and meta-regression analysis. EClinicalMedicine 2025, 81: 103122. PMID: 40115174, PMCID: PMC11925534, DOI: 10.1016/j.eclinm.2025.103122.Peer-Reviewed Original ResearchRotavirus-associated gastroenteritisRotavirus vaccine efficacyPredicting vaccine efficacyVaccine efficacyVaccine effectivenessVaccine performanceNational rotavirus immunization programImpact of rotavirus vaccinationRotavirus immunization programAffecting young childrenBill &Meta-regression analysisRandomized Controlled TrialsSystematic review of studiesEstimates of vaccine effectivenessRotavirus morbidityMelinda Gates FoundationRotavirus vaccineCohort studyLicensed vaccinesVaccine trialsDecreased efficacyControlled TrialsCase-controlLow-income settings
2023
Public Health Impacts of Vaccines for COVID-19 and Beyond: Opportunities to Overcome Technical and Regulatory Barriers for Randomized Trials.
Kennedy-Shaffer L. Public Health Impacts of Vaccines for COVID-19 and Beyond: Opportunities to Overcome Technical and Regulatory Barriers for Randomized Trials. American Journal Of Public Health 2023, 113: 778-785. PMID: 37104734, PMCID: PMC10262256, DOI: 10.2105/ajph.2023.307302.Peer-Reviewed Original ResearchConceptsPublic health impactCOVID-19 pandemicPopulation healthEvidence baseCOVID-19Health impactsInfectious disease outbreaksCommunity levelRandomized trialsIndividual levelRegulatory barriersPivotal trialsClinical benefitTrialsClinical trialsVaccine trialsPrevent infectionStrategic deploymentVaccineHealthSex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine
Cheung F, Apps R, Dropulic L, Kotliarov Y, Chen J, Jordan T, Langweiler M, Candia J, Biancotto A, Han K, Rachmaninoff N, Pietz H, Wang K, Tsang J, Cohen J. Sex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine. ELife 2023, 12: e80652. PMID: 36648132, PMCID: PMC9844983, DOI: 10.7554/elife.80652.Peer-Reviewed Original ResearchConceptsEarly innate responseVaccine recipientsPrior exposureInnate responseType I interferon signatureInfectious diseasesSeronegative vaccine recipientsType I IFN responseEarly antiviral responseNational InstituteInnate immune responseSystems immunology approachI IFN responseAdaptive immune phenotypesIntramural Research ProgramInterferon signatureAntibody titersVaccine trialsImmune phenotypeVirus vaccineNaive womenImmune responseSanofi PasteurDay 1Herpesvirus vaccine
2022
1056. Correlates of Omicron SARS-CoV-2 viral load: diagnostic and clinical implications
Pollett S, Richard S, Fries A, Malloy A, Ganesan A, Livezey J, Saunders D, Huprikar N, Mody R, Mende K, Lindholm D, Berjohn C, Rozman J, Jones M, Colombo C, Colombo R, Tribble D, Simons M, Agan B, Burgess T. 1056. Correlates of Omicron SARS-CoV-2 viral load: diagnostic and clinical implications. Open Forum Infectious Diseases 2022, 9: ofac492.897. PMCID: PMC9752607, DOI: 10.1093/ofid/ofac492.897.Peer-Reviewed Original ResearchViral loadVaccine trialsIII mAbsAstra ZenecaClinical severitySARS-CoV-2Associated with lower viral loadRNA abundanceSensory lossEffects of anatomic siteNasal swabsVaccination historyLongitudinal cohortOmicron SARS-CoV-2 infectionLow viral loadSore throat symptomsSARS-CoV-2 infectionLoss of smellMedian ageMultivariate linear regression modelNasal congestionClinical characteristicsPharyngeal symptomsClinical prognosticationSARS-CoV-2 variantsHIV-1 Vpu restricts Fc-mediated effector functions in vivo
Prévost J, Anand S, Rajashekar J, Zhu L, Richard J, Goyette G, Medjahed H, Gendron-Lepage G, Chen H, Chen Y, Horwitz J, Grunst M, Zolla-Pazner S, Haynes B, Burton D, Flavell R, Kirchhoff F, Hahn B, Smith A, Pazgier M, Nussenzweig M, Kumar P, Finzi A. HIV-1 Vpu restricts Fc-mediated effector functions in vivo. Cell Reports 2022, 41: 111624. PMID: 36351384, PMCID: PMC9703018, DOI: 10.1016/j.celrep.2022.111624.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityEffector functionsFc-mediated effector functionsHIV-1-infected cellsWild-type virusCorrelates of protectionRV144 vaccine trialHIV-1 infectionNon-neutralizing antibodiesFc effector functionsCell surface CD4Viral envelope glycoproteinsViral loadHumanized miceHumoral responseVaccine trialsCellular cytotoxicityHIV-1 VpuVpu expressionEnvelope glycoproteinInfected cellsNnAbsVirusVpuAdministrationEvaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings
Mulamba C, Williams C, Kreppel K, Ouedraogo J, Olotu A. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria Journal 2022, 21: 159. PMID: 35655174, PMCID: PMC9161629, DOI: 10.1186/s12936-022-04173-y.Peer-Reviewed Original ResearchConceptsEndemic settingsMalaria transmission-blocking vaccineHuman vaccine trialsTransmission-blocking vaccinesPublic health importanceMosquito vectorsMiddle-income settingsAnti-malarial drugsImmunological mechanismsCandidate vaccinesVaccine trialsHealthy individualsIncome settingsTransmission blockingHealth importanceMalaria controlMalaria parasitesVaccineLocal interventionsDrugsInterventionSettingSexual stagesPfs25DiseaseCOVID-19 vaccine perceptions in the initial phases of US vaccine roll-out: an observational study on reddit
Kumar N, Corpus I, Hans M, Harle N, Yang N, McDonald C, Sakai SN, Janmohamed K, Chen K, Altice FL, Tang W, Schwartz JL, Jones-Jang SM, Saha K, Memon SA, Bauch CT, Choudhury M, Papakyriakopoulos O, Tucker JD, Goyal A, Tyagi A, Khoshnood K, Omer S. COVID-19 vaccine perceptions in the initial phases of US vaccine roll-out: an observational study on reddit. BMC Public Health 2022, 22: 446. PMID: 35255881, PMCID: PMC8899002, DOI: 10.1186/s12889-022-12824-7.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccine perceptionsVaccine perceptionsCOVID-19 vaccination servicesVaccine trial dataUS vaccineDevelopment of interventionsVaccine trialsVaccination servicesObservational studyVaccine informationTrial dataVaccineConclusionsOur findingsVaccine-related keywordsCOVID-19Vaccine misinformationEarly phaseInitial phaseAssociationFurther researchCommunication campaignsVaccinationResultsTherePrevalenceMethodsWeCombining Cellular Immunology With RNAseq to Identify Novel Chlamydia T-Cell Subset Signatures
Johnson RM, Asashima H, Mohanty S, Shaw AC. Combining Cellular Immunology With RNAseq to Identify Novel Chlamydia T-Cell Subset Signatures. The Journal Of Infectious Diseases 2022, 225: 2033-2042. PMID: 35172331, PMCID: PMC9159333, DOI: 10.1093/infdis/jiac051.Peer-Reviewed Original ResearchConceptsProtective T cell clonesAntibacterial effector mechanismsT cells residentB cell helpT cell clonesCytokine polarizationImmune miceIL-10Protective immunityVaccine trialsIL-13Surrogate biomarkerEffector mechanismsGenital tractT cellsVaccine candidatesChlamydia trachomatisCells residentHelper functionCellular immunologyMouse studiesHuman investigationsReproductive tractGranzyme A.Investigational data
2021
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation
Sharp T, Anderson K, Katzelnick L, Clapham H, Johansson M, Morrison A, Harris E, Paz-Bailey G, Waterman S. Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. The Lancet Infectious Diseases 2021, 22: e42-e51. PMID: 34265259, PMCID: PMC11379041, DOI: 10.1016/s1473-3099(20)30871-9.Peer-Reviewed Original ResearchConceptsDengue virus infectionSevere dengueVirus infectionDisease severityAnti-dengue virus antibodiesMajor organ failureHospital admissionOrgan failureVaccine evaluationClinical spectrumVaccine trialsPrevious infectionRisk factorsVirus antibodiesClinical studiesClinical practiceDengue virusStudy participantsInfectionLack of specificityHost factorsVirus characteristicsDengueEpidemiologyRange of agesIdentification of causal intervention effects under contagion
Cai X, Loh WW, Crawford FW. Identification of causal intervention effects under contagion. Journal Of Causal Inference 2021, 9: 9-38. PMID: 34676152, PMCID: PMC8528235, DOI: 10.1515/jci-2019-0033.Peer-Reviewed Original ResearchIntervention effectsInfectious disease transmission dynamicsInfection outcomesDisease transmission dynamicsHIV vaccine trialsInfectious disease outcomesTransmission dynamicsEffects of interventionsVaccine effectsIntervention trialsVaccine trialsClinical evaluationDisease outcomeOutcome dataTrialsTreatment effectsOutcomesCausal estimandsEmpirical trialPartnership modelInfectionBinary outcome data
2020
Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside
Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal Of Leukocyte Biology 2020, 108: 1455-1489. PMID: 32557857, DOI: 10.1002/jlb.5bt0420-585rr.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMode of deliveryCancer vaccinesImmune checkpoint blockade agentsCheckpoint blockade agentsDifferent cancer vaccinesNeoantigen-based vaccinesRecent preclinical advancesCancer vaccine trialsCancer vaccine fieldLittle clinical activityPromising preclinical resultsMultiple cancer typesCheckpoint blockadeImmunotherapeutic trialsPreclinical advancesTherapeutic vaccinesVaccine trialsClinical activityPreclinical resultsClinical strategiesTherapeutic outcomesVaccine fieldClinical effortsVaccineCancer types
2015
Epidemiological Markers for Interactions Among Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Upper Respiratory Tract Carriage
Lewnard JA, Givon-Lavi N, Huppert A, Pettigrew MM, Regev-Yochay G, Dagan R, Weinberger DM. Epidemiological Markers for Interactions Among Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Upper Respiratory Tract Carriage. The Journal Of Infectious Diseases 2015, 213: 1596-1605. PMID: 26704617, PMCID: PMC4837906, DOI: 10.1093/infdis/jiv761.Peer-Reviewed Original ResearchMeSH KeywordsCarrier StateChild, PreschoolFemaleHaemophilus InfectionsHaemophilus influenzaeHeptavalent Pneumococcal Conjugate VaccineHumansInfantIsraelLongitudinal StudiesMalePneumococcal InfectionsRespiratory Tract InfectionsRisk FactorsStaphylococcal InfectionsStaphylococcus aureusStreptococcus pneumoniaeVaccines, ConjugateConceptsPneumococcal serotype replacementH. influenzaeSerotype replacementS. pneumoniaeHaemophilus influenzaeStreptococcus pneumoniaePneumococcal conjugate vaccine trialUpper respiratory tract carriagePneumococcal vaccine introductionS. aureus carriageMonths of ageStaphylococcus aureusPCV7 recipientsAureus carriageVaccine introductionVaccine trialsCarriage patternsConfounding factorsClinical interventionsInfluenzaeEpidemiological markersBedouin childrenPneumoniaeCarriageS. aureusIdentification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials
Baggs J, Yousey-Hindes K, Ashley ED, Meek J, Dumyati G, Cohen J, Wise ME, McDonald LC, Lessa FC. Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials. Vaccine 2015, 33: 6241-6249. PMID: 26450660, PMCID: PMC4702247, DOI: 10.1016/j.vaccine.2015.09.078.Peer-Reviewed Original ResearchConceptsEmerging Infections ProgramHigh-risk groupRisk groupsRisk scoreIndex hospitalizationHospital dischargeDerivation cohortVaccine trialsValidation cohortDifficile infectionCox proportional hazards modelRisk of CDIAcute care hospitalizationIdentification of patientsClostridium difficile infectionHospital discharge dataNumber of hospitalizationsLow-risk groupProportional hazards modelLarge academic centerAdmission diagnosisPrimary outcomeInpatient stayPatient populationPharmacy data
2014
The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso
Tinto H, Valea I, Sorgho H, Tahita M, Traore M, Bihoun B, Guiraud I, Kpoda H, Rouamba J, Ouédraogo S, Lompo P, Yara S, Kabore W, Ouédraogo J, Guiguemdé R, Binka F, Ogutu B. The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso. Malaria Journal 2014, 13: 113. PMID: 24655351, PMCID: PMC3994337, DOI: 10.1186/1475-2875-13-113.Peer-Reviewed Original ResearchConceptsClinical research unitMalaria vaccine trialsClinical trial platformDemographic Surveillance SystemResource-poor settingsClinical research activitiesClinical laboratory servicesVaccine trialsHealth workersNanoroMalaria controlClinical researchNew drugsTrial platformHealth careLaboratory servicesResearch UnitSurveillance systemSaharan AfricaStudy dataTotal populationRural AfricaActive advocacyBurkina FasoPopulation
2013
Generating protective immunity against genital herpes
Shin H, Iwasaki A. Generating protective immunity against genital herpes. Trends In Immunology 2013, 34: 487-494. PMID: 24012144, PMCID: PMC3819030, DOI: 10.1016/j.it.2013.08.001.Peer-Reviewed Original ResearchConceptsGenital herpesHerpes simplex virus infectionSimplex virus infectionSignificant risk factorsClinical vaccine trialsRecurrent symptomsHSV infectionProtective immunityViral sheddingVaccine trialsRisk factorsChronic diseasesVirus infectionHIV-1Clear infectionAntiviral drugsHost responseHerpesVaccine designInfectionMillions of peopleSpread of diseaseDiseaseRecent studiesVaccineDengue dynamics and vaccine cost-effectiveness in Brazil
Durham DP, Mbah M, Medlock J, Luz PM, Meyers LA, Paltiel AD, Galvani AP. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine 2013, 31: 3957-3961. PMID: 23791696, PMCID: PMC3755607, DOI: 10.1016/j.vaccine.2013.06.036.Peer-Reviewed Original ResearchConceptsVaccination costsDengue vaccine trialsVaccine efficacyTotal vaccination costDengue vaccinationCost-effectiveness analysisPotential vaccination policiesVaccine trialsPay thresholdsVaccine efficacy scenariosOptimal allocationLow vaccine efficacyLatest clinical trialsOptimistic scenarioTrial estimatesVaccination coverageEfficacy scenariosClinical trialsAvailable dosesVaccination policyFurther trialsVaccination modelHerd immunityVaccinationCost
2009
Sexual risk behaviour of the first cohort undergoing screening for enrolment into Phase I/II HIV vaccine trials in South Africa
Andersson K, Van Niekerk R, Niccolai L, Mlungwana O, Holdsworth I, Bogoshi M, McIntyre J, Gray G, Vardas E. Sexual risk behaviour of the first cohort undergoing screening for enrolment into Phase I/II HIV vaccine trials in South Africa. International Journal Of STD & AIDS 2009, 20: 95-101. PMID: 19182054, PMCID: PMC3556817, DOI: 10.1258/ijsa.2008.008207.Peer-Reviewed Original ResearchConceptsPhase I/II HIV vaccine trialHIV vaccine trialsRisk behaviorsVaccine trialsPhase I/II trialPhase III efficacy trialHIV-positive partnerRisk reduction counsellingSexual risk behaviorsRecreational drug useHigh-risk behaviorsHeavy alcohol useMore sex partnersAnonymous partnersII trialMale genderHeterosexual cohortsEfficacy trialsMale volunteersFemale volunteersAdditional recruitment methodSex partnersDrug useMultivariate analysisCondom use
2005
Enrollment of Racial/Ethnic Minorities in NIAID-Funded Networks of HIV Vaccine Trials in the United States, 1988 to 2002
Djomand G, Katzman J, diTommaso D, Hudgens M, Counts G, Koblin B, Sullivan P. Enrollment of Racial/Ethnic Minorities in NIAID-Funded Networks of HIV Vaccine Trials in the United States, 1988 to 2002. Public Health Reports 2005, 120: 543-548. PMID: 16224987, PMCID: PMC1497755, DOI: 10.1177/003335490512000509.Peer-Reviewed Original ResearchConceptsHIV vaccine trialsPhase I trialVaccine trialsI trialHIV-1-uninfected participantsPreventive HIV vaccine trialsPhase II trialHIV vaccine researchNational Institute of AllergyInstitute of AllergySelf-reported risk behaviorsPhase III trialAuthors reviewed dataHIV infectionRacial/ethnic minority participantsHIV-1Uninfected participantsIdentified trialsHigh riskVaccine researchEfficacy trialsRisk behaviorsMinority participantsPooled data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply